CompletedNCT00391222
Long-acting risperidone to prevent mood episodes in bipolarity type I
About this title
A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder
Read the official source — NCT00391222Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Baoding and 62 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 585
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- China, Colombia, Germany, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00391222
- Official title
Show the full official title
A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder
Get this study by email
Recruitment & locations
CompletedBaoding, China · Beijing, China · Guangzhou, China
61 more locations
- Nanjing, China
- Shanghai, China
- Suozhou, China
- Wuhan, China
- Barranquilla Atlantico, Colombia
- Bello Antioquia, Colombia
- Bogotá, Colombia
- Bogotá S/N, Colombia
- Medellin Antioquia, Colombia
- Pereira Risaralda, Colombia
- Freiburg im Breisgau, Germany
- Hildesheim, Germany
- Oranienburg, Germany
- Athens, Greece
- Ahmedabad, India
- Bangalore, India
- Chennai, India
- Hyderabad, India
- Ludhiana, India
- Mangalore, India
- Mumbai, India
- New Delhi, India
- Pune, India
- Varanasi, India
- Jakarta, Indonesia
- Amman, Jordan
- Beirut, Lebanon
- Johor Bahru, Malaysia
- Kuala Lumpur, Malaysia
- Mexico City, Mexico
- Mérida, Mexico
- Monterrey, Mexico
- Puebla City, Mexico
- Tabasco, Mexico
- Tampico, Mexico
- Zapopan, Mexico
- Lima, Peru
- Lima Lima, Peru
- Iloilo City, Philippines
- Mandaluyong, Philippines
- Mandaue City, Philippines
- Arkhangelsky District, Russia
- Chelyabinsk, Russia
- Izhevsk, Russia
- Kazan’, Russia
- Moscow, Russia
- Moscow Region, Russia
- Nizny Novgorod, Russia
- Orenburg, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Stavropol Na, Russia
- Tomsk Na, Russia
- Voronezh, Russia
- Bloemfontein, South Africa
- Cape Town, South Africa
- Durban, South Africa
- Pretoria, South Africa
- Tainan, Taiwan
- Taipei, Taiwan
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Janssen Pharmaceutica N.V., Belgium.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine, Placebo and Risperidone Long Acting Injectable (LAI).
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolarity type I Pat...
A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolarity